Skip to content
OpenCapital
Get started

Senseonics Holdings, Inc. SENS US — Revenue

Other financials

Income statement

See full
Revenue$11.7M+87.2%
Gross profit$6.9M+361%
Operating income-$31.8M-136%
Net income-$32.3M-127%
EPS (diluted)-$0.71-77.5%

Balance sheet

See full
Cash & equivalents$29.6M-24.7%
Total debt$43.1M+5.0%
Total equity$34.3M-2.4%
Total assets$102.9M+17.9%

Cash flow

See full
Operating cash flow-$32.0M-99.2%
CapEx$111.0K-74.4%
Free cash flow-$32.1M-94.6%

Valuation

See full
Market cap$296.51M-21.4%
Enterprise value$310.04M-19.9%
P/S7.3×-7.5×

Profitability

See full
Gross margin52.1%+44.9pp
Operating margin-213%-46.7pp
Net margin-214.1%-51.2pp
FCF margin-186.4%-37.0pp

Returns & leverage

See full
Return on equity-250.7%-19.0pp
Debt / equity1.3×+0.1×
Current ratio3.5×-3.4×

Where this comes from

Reported directly by Senseonics Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Senseonics Holdings, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Senseonics Holdings, Inc. 's us — revenue.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Senseonics Holdings, Inc. 's US — revenue?
Senseonics Holdings, Inc. (SENS) reported US — revenue of $9.33M in Q1 2026.
How has Senseonics Holdings, Inc. 's US — revenue changed year-over-year?
Senseonics Holdings, Inc. 's US — revenue increased by 107.6% year-over-year, from $4.5M to $9.33M.
What is the long-term trend for Senseonics Holdings, Inc. 's US — revenue?
Over 4 years (2021 to 2025), Senseonics Holdings, Inc. 's US — revenue has grown at a 81.7% compound annual growth rate (CAGR), from $2.56M to $27.91M.
What does US — revenue mean?
This metric represents the total gross revenue generated from the sale of goods and services within the United States geographic segment, excluding any collected sales or value-added taxes. It serves as a primary indicator of the company's commercial traction and market penetration for its core medical technology offerings in the domestic market. Tracking this figure allows investors to assess the growth trajectory of the business independent of international market volatility.